

manufactured for sale in the country without a Licence granted by the State Licensing Authorities appointed by respective State Governments, under the provisions of Drugs and Cosmetics Act, 1940 and Rules, 1945 made thereunder. The manufacture for sale of drugs is regulated through a system of inspection and licensing and regular inspections thereafter. The drug manufacturer is required to comply with the conditions of license and follow Good Manufacturing Practices (GMP) to ensure that the drugs manufactured by them are of standard quality.

Rates of medicines at Jan Aushadhi Stores

3039. SHRI PALVAI GOVARDHAN REDDY: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

- (a) whether it is a fact that Jan Aushadhi Stores proposed to supply 361 generic medicines;
- (b) if so, whether it is also a fact that even after six years of its implementation, the Ministry has not finalized rates for more than 100 medicines, if so, the reasons therefor; and
- (c) who is responsible for this and what action the Ministry has taken in this regard?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI HANS RAJ GANGARAM AHIR): (a) Yes, Sir. Under the New Business Plan, approved in 2013, 361 generic medicines are proposed to be supplied under the Jan Aushadhi Scheme.

(b) and (c) The Jan Aushadhi scheme, as originally conceived in 2008 provided for procurement of supplies only from CPSUs. However, since the CPSUs were having in-house manufacturing capability for only 138 medicines out of 361 medicines proposed to be supplied from Jan Aushadhi stores, the Department of Pharmaceuticals after reviewing the entire scheme in August, 2013 provided for procurement of medicines from private manufacturers in respect of medicines which the CPSUs are not in a position to supply.

After the approval of New Business Plan, an immediate action was initiated by Bureau of Pharma Public Sector Undertakings of India (BPPI), implementing agency for the Scheme, by floating tender for procurement of medicines from private manufacturers following the GFR and CVC guidelines. After floating two tenders, rate Contracts/price fixation has been finalized in respect of 259 medicines. The medicines in respect of the remaining items which could not be finalized on account of either single quote or no quote, are being retendered.